Equity Overview
Price & Market Data
Price: $0.74
Daily Change: -$0.001 / 0.14%
Daily Range: $0.74 - $0.74
Market Cap: $5,614,910
Daily Volume: 568
Performance Metrics
1 Week: 2.19%
1 Month: -17.33%
3 Months: -33.24%
6 Months: -53.10%
1 Year: -45.11%
YTD: -24.46%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.